GLRA1

Glycine receptor subunit alpha-1 · P23415 · GLRA1 on Sugi Atlas →

19,915 patent compounds predicted against GLRA1, 14,913 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Strychnine (SCHEMBL235087)	0.91	15/20
Strychnine (SCHEMBL578374)	0.93	14/20
Strychnine (SCHEMBL578475)	0.90	14/20
Strychnine (SCHEMBL1049901)	0.90	14/20
Strychnine (SCHEMBL1049902)	0.90	14/20
Brucine (SCHEMBL113229)	0.73	14/20
Brucine (SCHEMBL524833)	0.72	14/20
Brucine (SCHEMBL341490)	0.69	14/20
Brucine (SCHEMBL577757)	0.69	14/20
Brucine (SCHEMBL577756)	0.67	14/20
Strychnine (SCHEMBL93798)	1.00	13/20
Strychnine (SCHEMBL184168)	0.98	13/20
SCHEMBL933597	0.58	11/20
SCHEMBL1006125	0.37	9/20
SCHEMBL245921	0.72	5/20
Ginkgolide A (SCHEMBL340233)	1.00	4/20
Ginkgolide A (SCHEMBL340234)	1.00	4/20
Ginkolide B (SCHEMBL464783)	1.00	3/20
Ginkolide B (SCHEMBL464784)	1.00	3/20
Bilobalide (SCHEMBL285824)	0.32	3/20

Clinical trials — most relevant to GLRA1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effects of Levetiracetam on Alcohol Dependent Subjects	PHASE4	COMPLETED
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.	PHASE4	UNKNOWN
Effects of GABA-a-Agonists on Pain Mechanisms: An Experimental Study in Healthy Volunteers	PHASE3	COMPLETED
Dronabinol in Trichotillomania and Other Body Focused Repetitive Behaviors	PHASE2/PHASE3	COMPLETED
Memantine for Refractory OCD Patients	PHASE3	UNKNOWN
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia	PHASE2	COMPLETED
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders	PHASE2	COMPLETED
Therapeutic Efficacy of L-Ornithine L-Aspartate Infusion in Patients With Acute Liver Failure	PHASE2	UNKNOWN
Safety and Efficacy of Ramelteon and Doxepin in Subjects With Chronic Insomnia	PHASE2	COMPLETED
High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia	PHASE2	UNKNOWN
Efficacy and Safety of Ramelteon Combined With Gabapentin in Treating Patients With Insomnia	PHASE2	COMPLETED
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder	PHASE2	COMPLETED
PET Imaging of Brain mGluR5 Receptors Using [18F]SP203	PHASE1	COMPLETED
Riluzole in Women With Stage I, Stage II, or Stage IIIA Breast Cancer	PHASE1	WITHDRAWN
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia	PHASE1	COMPLETED
Excitatory Amino Acids and Activated Microglia After Traumatic Brain Injury: a (R)-[11C]PK11195 PET Study	PHASE1	UNKNOWN
Brain Imaging, Genetics and Treatment for Major Depression	PHASE1	WITHDRAWN
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine	EARLY_PHASE1	COMPLETED
D-aspartate and Therapeutic Exercise	EARLY_PHASE1	UNKNOWN
Imaging the Effects of Zolpidem and Alprazolam in Healthy Volunteers at 3T	EARLY_PHASE1	UNKNOWN
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease	nan	COMPLETED
Acute Asthma Responsiveness and B2 Adrenergic Receptors Polymorphisms	nan	COMPLETED
PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX	nan	COMPLETED
Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation	nan	UNKNOWN
CRF vs WCRF or PRF-DRG in CLBP of FJ Origin and RFA Failure of MBDR: Central Sensitization and Aberrant Nerve Sprouting	nan	UNKNOWN
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING
Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy)	nan	UNKNOWN
Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia	nan	UNKNOWN
Effect of D-cycloserine on Extinction of Fear Conditioning	nan	COMPLETED
Epidemiology of Autoimmune Encephalitides and Paraneoplastic Neurological Syndromes in Sweden	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a GLRA1 binder may also engage these)

Protein	Name	Similarity
Q64018	—	1.000	Q64018 →
P57695	—	1.000	P57695 →
GLRA2	Glycine receptor subunit alpha-2	1.000	landscape →
P07727	—	1.000	P07727 →
GLRA3	Glycine receptor subunit alpha-3	1.000	landscape →
Q91XP5	—	1.000	Q91XP5 →
P22771	—	1.000	P22771 →
F1R8P4	—	1.000	F1R8P4 →
O93430	—	1.000	O93430 →
P24524	—	1.000	P24524 →
Q61603	—	1.000	Q61603 →
Q7TNC8	—	0.999	Q7TNC8 →
G5EBR3	—	0.996	G5EBR3 →
Q17328	—	0.996	Q17328 →
P18506	—	0.994	P18506 →
P22933	—	0.993	P22933 →
P91730	—	0.992	P91730 →
GABRD	Gamma-aminobutyric acid receptor subunit delta	0.991	landscape →
P26714	—	0.988	P26714 →
P48168	—	0.987	P48168 →
Q94900	—	0.987	Q94900 →
A8WQK3	—	0.986	A8WQK3 →
O18276	—	0.986	O18276 →
GLRB	Glycine receptor subunit beta (Glycine recept	0.985	landscape →
P26153	—	0.985	P26153 →
Q5EA06	—	0.985	Q5EA06 →
Q8QZW7	—	0.985	Q8QZW7 →
P02712	—	0.985	P02712 →
P20781	—	0.984	P20781 →
GABRP	Gamma-aminobutyric acid receptor subunit pi (	0.984	landscape →